2024
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
Ghobadi A, Jacobson C, McGuirk J, Shah N, Rossi J, Buchholz T, Bachier-Rodriguez L, Baird J, Diefenbach C, Farooq U, Hernandez-Ilizaliturri F, Isufi I, Patel K, Neelapu S, Sauter C, Spiegel J, Tees M, Timmerman J, Laport G, Frank M. Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Journal Of Clinical Oncology 2024, 42: tps7085-tps7085. DOI: 10.1200/jco.2024.42.16_suppl.tps7085.Peer-Reviewed Original ResearchCAR-T cell therapyCD19-directed CAR T-cell therapyDiffuse large B-cell lymphomaT-cell therapyB-cell lymphomaCytokine release syndromeOverall response rateLarge B-cell lymphomaR/R LBCLT cells/kgAdverse eventsAutologous CAR-T cell therapyHigh grade B-cell lymphomaBispecific T-cell engager antibodiesPrimary mediastinal B-cell lymphomaPhase 2 open-labelRecommended phase 2 doseAllogeneic stem cell transplantationGrade B-cell lymphomaMediastinal B-cell lymphomaInduce long-term remissionT-cell engager antibodiesResponse ratePhase 2 doseComplete response rateAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelMulticenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR/R large B-cell lymphomaLarge B-cell lymphomaCenter for International Blood and Marrow Transplant ResearchCytokine release syndromeDuration of responseLiso-celData cutoffRisk of cytokine release syndromeCAR-T cell productsDuration of response rateHigh-risk disease featuresMedian duration of responseReal-world population of patientsB-cell lymphomaTreated with corticosteroidsCAR+ T cellsMarrow Transplant ResearchT cell productionStudy of US patientsPopulation of patientsOne-time infusionReal-world populationReal-world studyCellular therapy registry
2023
Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Palomba M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood 2023, 142: 104. DOI: 10.1182/blood-2023-180242.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR LBCLLarge B-cell lymphomaCytokine release syndromeProgression-free survivalDuration of responseReal-world clinical effectivenessHigh-grade B-cell lymphomaLiso-celInternational Prognostic IndexB-cell lymphomaOverall survivalSystemic therapyReal-world studyData cutoffPostmarketing studyMedian timeClinical effectivenessClinical studiesFavorable benefit/risk profileReal-world settingMedian DORMedian progression-free survivalBenefit/risk profileCAR T-cell products